CYPB - Cypress BioScience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dwight martin who wrote (518)	7/23/1999 12:18:00 AM
From: dwight martin	Read Replies (1) of 586

What a dead thread! biospace.com •Fujisawa Pharmaceutical Enrolls First Patient In Phase III Rheumatoid Arthritis Study Fujisawa Healthcare, Inc. (Fujisawa) announced today the enrollment of the first patient in a Phase III clinical study for rheumatoid arthritis. Fujisawa is sponsoring the Phase III clinical trials in the United States to assess the efficacy and safety of tacrolimus in rheumatoid arthritis patients who have demonstrated resistance to, or intolerance of, disease-modifying anti-rheumatic drugs. Approximately 50 centers are expected to participate in this study with an enrollment goal of 450 patients. The patient population will consist of adult patients, 16 years or older, with a diagnosis of rheumatoid arthritis for at least six months. Rheumatoid arthritis is an autoimmune disorder [more].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next